PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayPreclinical investigations across leukemia models demonstrate that anti-thymocyte globulin, an antibody preparation conventionally used to prevent graft-versus-host disease, exerts potent antileukemic activity against T-cell acute lymphoblastic leukemia through tumor necrosis factor alpha signaling. Researchers evaluated the therapeutic efficacy of anti-thymocyte globulin across human leukemia cell lines, patient-derived xenografts, and primary patient samples, revealing that the agent triggers both apoptotic and necroptotic cell death regardless of surface CD3 receptor expression. While responses in surface CD3-positive malignancies rely upon intense T-cell receptor activation cascades, investigators established that anti-thymocyte globulin also induces cytotoxicity in surface CD3-negative blasts by activating a tumor necrosis factor alpha and nuclear factor kappa B transcriptional program. Furthermore, experimental findings show that resistance mediated by cellular inhibitors of apoptosis can be overcome by combining anti-thymocyte globulin with the bivalent antagonist birinapant.
T-cell acute lymphoblastic leukemia represents an aggressive hematological malignancy arising from the leukemic transformation of thymic progenitor cells arrested at discrete differentiation stages due to diverse genetic lesions. Although standard front-line combination chemotherapy achieves initial remissions, approximately twenty to thirty percent of pediatric patients and forty percent of adult patients experience disease relapse, which confers a dismal clinical prognosis. The development of targeted immunotherapies for T-cell acute lymphoblastic leukemia has lagged behind advancements in B-cell precursor acute lymphoblastic leukemia or acute myeloid leukemia, primarily because malignant T cells share critical surface antigens with normal T cells. Therapeutic strategies such as chimeric antigen receptor T cells targeting CD7 frequently cause severe fratricidal destruction among engineered effector cells and profound T-cell aplasia, while earlier monoclonal antibody approaches targeting CD3 epsilon suffered from clinically unacceptable systemic toxicities.
To address this therapeutic bottleneck, investigators explored the repositioning of anti-thymocyte globulin, clinically marketed as Thymoglobulin, which consists of a polyclonal cocktail of purified rabbit immunoglobulin G generated against human thymocytes. The preparation has accumulated decades of routine clinical usage for mitigating acute graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation, preventing graft rejection following solid organ transplantation, and treating severe aplastic anemia. Because anti-thymocyte globulin contains a broad repertoire of immunoglobulins directed against numerous distinct surface glycoproteins present on human thymocytes, researchers hypothesized that its multi-targeted binding profile could overcome the antigen escape and clonal heterogeneity that typically undermine single-epitope targeted therapies. By leveraging this established polyclonal formulation, the study evaluated whether direct administration of anti-thymocyte globulin could trigger cytotoxic intracellular signaling cascades inside transformed leukemic blasts.
Initial experimental assays demonstrated that anti-thymocyte globulin exerted robust cytotoxicity against surface CD3-positive T-cell acute lymphoblastic leukemia cell lines and sixteen patient-derived xenografts exposed ex vivo. Following brief exposure to anti-thymocyte globulin, surface CD3-positive cells mounted an immediate T-cell receptor signaling cascade that closely mirrored signaling dynamics observed following stimulation with established anti-CD3 antibodies or anti-CD3 and anti-CD28 magnetic dynabeads. Phosphokinase antibody arrays performed within fifteen minutes of exposure revealed rapid phosphorylation and activation of critical downstream kinases, including lymphocyte cell-specific protein-tyrosine kinase Lck, zeta-chain-associated protein kinase ZAP70, mitogen-activated protein kinases p38 and Erk, c-Jun N-terminal kinase, protein kinase B Akt, and ribosomal S6 kinase RSK. In parallel, treated leukemic cells markedly upregulated surface expression of CD69, an established marker of acute cellular activation, indicating that the multi-antigen cocktail functionally engages the canonical antigen receptor machinery.
To confirm that receptor engagement is essential for cytotoxicity in surface CD3-positive disease, researchers treated leukemic cells with dasatinib, a pharmacological pan-Src family kinase inhibitor that selectively suppresses Lck activity and halts downstream signaling. Pharmacological inhibition with dasatinib partially rescued leukemic cells from anti-thymocyte globulin-mediated death, while immunoprecipitation coupled with mass spectrometry identified components of the CD3 complex and human leukocyte antigen class I molecules among the principal binding partners. A genome-wide CRISPR-Cas9 screening campaign conducted in Cas9-expressing JURKAT cells across five days of drug exposure identified ten positively selected mediator genes whose inactivation conferred resistance. Notably, eight of these top ten positive hits corresponded directly to components of the T-cell receptor apparatus. Subsequent targeted shRNA knockdown and CRISPR knockout against candidate genes, including CD3 epsilon, LAT, LCK, and ZAP70, attenuated drug-induced cell death, confirming that intact receptor signaling mediates cytotoxicity in this subtype.
In vivo validation using immunocompromised NSG mice xenografted with luciferase-expressing human ALL-SIL/TCR-HY cells corroborated these findings while demonstrating substantial advantages over conventional monoclonal anti-CD3 therapy. While control mice treated with polyclonal rabbit immunoglobulin rapidly succumbed to aggressive leukemia, animals treated daily with anti-thymocyte globulin exhibited profound suppression of tumor burden and markedly extended overall survival times. Remarkably, anti-thymocyte globulin demonstrated stronger antileukemic activity than muromonab OKT3 and successfully maintained disease control in mice engrafted with cells engineered with short hairpin RNA silencing of linker for activation of T cells LAT, a genetic alteration under which OKT3 completely failed. Furthermore, anti-thymocyte globulin therapy effectively controlled leukemic outgrowth in two aggressive patient-derived xenograft models of surface CD3-positive leukemia, designated UPNT420 and UPNT419, significantly extending survival and confirming that the polyclonal agent exerts superior antineoplastic control compared to monospecific antibodies in living animal models.
Critically, the investigators discovered that the antileukemic efficacy of anti-thymocyte globulin extends beyond surface CD3-positive malignancies into surface CD3-negative T-cell acute lymphoblastic leukemia. When evaluating surface CD3-negative cell lines, ALL-SIL displayed pronounced sensitivity, prompting ex vivo screening across twenty-eight distinct patient-derived xenograft models lacking surface CD3 expression. Among these twenty-eight patient xenografts, fourteen demonstrated marked cytotoxicity characterized by a greater than forty percent reduction in viability compared to controls, eight exhibited moderate responses, and six proved refractory. In vivo administration in NSG mice transplanted with five independent surface CD3-negative xenografts confirmed significant reductions in peripheral blood human blast percentages and substantial prolongations of survival. Detailed comparisons of maturation stages, oncogenetic drivers, and clinical cohorts, including thirty patient specimens from the GRAALL-03/05 or FRALLE2000T trials, revealed no confounding correlations, demonstrating that therapeutic responsiveness occurs independently of traditional molecular classifications.
To unravel the alternative molecular mechanisms driving cell death in blasts lacking functional surface antigen receptors, researchers conducted transcriptomic profiling via bulk RNA sequencing on sensitive cell lines and xenografts. Rapid exposure to anti-thymocyte globulin induced prominent upregulation of transcription factors belonging to early growth response EGR and immediate early response IER gene families, alongside downstream target transcripts such as NR4A1, DUSP2, and FOS, while selectively repressing oxidative stress responders including TXNIP. Gene ontology and gene set enrichment analyses revealed that sensitive samples uniquely shared an activated transcriptional signature governed by tumor necrosis factor alpha signaling via nuclear factor kappa B and apoptotic pathways. A complementary genome-wide CRISPR screen performed in CD3E-knockout cells identified essential roles for interferon alpha and gamma signaling mediators, TAP genes, and tumor necrosis factor superfamily member TNFSF4, confirming that death signaling converges upon common inflammatory networks.
Biochemical characterization of cell death execution revealed that anti-thymocyte globulin simultaneously engages both apoptotic and necroptotic machinery in sensitive leukemic cells. Apoptome arrays and Western blot analyses demonstrated rapid proteolytic cleavage of executioner caspase-3 and initiator caspase-8 within eight hours of treatment, accompanied by increased expression of tumor necrosis factor receptor superfamily member 1A. Concurrently, sensitive cells exhibited rapid phosphorylation of mixed lineage kinase domain-like protein MLKL at serine 358, a definitive molecular hallmark of necrosome assembly and necroptosis execution. Enzyme-linked immunosorbent assays demonstrated enhanced autocrine secretion of tumor necrosis factor alpha in culture supernatants of sensitive JURKAT cells and three out of five patient xenografts. Neutralization of extracellular cytokine using etanercept significantly rescued cell viability, while dual genetic ablation of MLKL and caspase-8 using CRISPR-Cas9 conferred robust protection against cytotoxicity, demonstrating that apoptosis and necroptosis operate as compensatory execution pathways.
Temporal transcriptomic profiling using density-based spatial clustering across a twenty-four-hour time course identified critical negative feedback regulators that restrict drug-induced cytotoxicity and contribute to therapeutic resistance. In sensitive cells surviving prolonged drug exposure, as well as in inherently resistant cell lines such as RPMI-8402, expression of BIRC3, encoding the anti-apoptotic ubiquitin ligase cellular inhibitor of apoptosis 2, was strongly induced alongside BIRC2 and XIAP. To neutralize this resistance mechanism, researchers combined anti-thymocyte globulin with birinapant, a bivalent SMAC mimetic that induces proteasomal degradation of cellular inhibitors of apoptosis. Combining anti-thymocyte globulin with birinapant restored catastrophic caspase-8 activation and cell death in resistant cells. In ex vivo tests encompassing twenty-three patient-derived xenografts, the combination significantly lowered viability in thirteen of sixteen resistant specimens and produced synthetic lethality with Bliss synergy scores exceeding ten across six models, while in vivo combination therapy substantially improved overall survival in engrafted mice.
The clinical relevance of this dual-targeting strategy was confirmed in fresh primary leukemic specimens isolated from twenty-five individual patients diagnosed with relapsed or refractory T-cell acute lymphoblastic leukemia. When challenged ex vivo with anti-thymocyte globulin monotherapy, fifteen of the twenty-five patient specimens demonstrated sensitivity, corresponding to an overall response rate of sixty percent. However, the addition of birinapant elevated the overall response rate to eighty-four percent, successfully inducing significant cytotoxic responses in twenty-one of the twenty-five patient samples. Crucially, specimens exhibiting the lowest baseline responsiveness to single-agent anti-thymocyte globulin demonstrated the most pronounced therapeutic synergy when paired with birinapant, highlighting the capacity of inhibitor of apoptosis degradation to convert refractory phenotypes into drug-sensitive targets. These collective findings establish a compelling preclinical rationale for repurposing anti-thymocyte globulin in combination with SMAC mimetics to overcome antigen escape and restore programmed cell death in refractory hematological malignancies.
Subject of Research: Antileukemic efficacy and mechanisms of anti-thymocyte globulin and birinapant in T-cell acute lymphoblastic leukemia
Article Title: Anti-thymocyte globulin triggers TNF-dependent cell death in T-cell acute lymphoblastic leukemia
Article References: Dourthe, M. E., Latiri, M., Lengliné, E., Charbonnier, G., Saji, C., Huré, G., Gillet, C., Doss, J., Touzart, A., Courtois, L., Cieslak, A., Simonin, M., Ifrah, N., Dombret, H., Hermine, O., Boissel, N., Baruchel, A., Ghysdael, J., Macintyre, E., … Asnafi, V. (2026). Anti-thymocyte globulin triggers TNF-dependent cell death in T-cell acute lymphoblastic leukemia. Nature Communications, 17(1), Article 10983. https://doi.org/10.1038/s41467-026-77027-9
Image Credits: AI Generated
DOI: 10.1038/s41467-026-77027-9
Keywords: anti-thymocyte globulin, T-cell acute lymphoblastic leukemia, birinapant, TNF-alpha signaling, apoptosis, necroptosis, SMAC mimetics, caspase-8, MLKL phosphorylation, T-cell receptor signaling, patient-derived xenografts, relapsed refractory leukemia, c-IAP1, c-IAP2, immunotherapy, Thymoglobulin, NF-kappaB pathway, CRISPR-Cas9 screen


57 minutes ago
1




















English (US) ·
French (CA) ·